Computerized clinical decision support systems, or CDSS, represent a paradigm shift in
healthcare today. CDSS are used to augment clinicians in their complex decision-making …

The demonstration that immune and epithelial cells can discriminate between different
microbial species has extended our understanding of the actions of probiotics beyond simple …

Inflammatory bowel diseases (IBD), which consists of Crohn disease and ulcerative colitis,
are chronic inflammatory conditions of the gas-trointestinal tract. In genetically susceptible …

Background Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective
maintenance therapy for patients with Crohn's disease without fistulas. It is not known …

Background The efficacy of vedolizumab, an α 4 β 7 integrin antibody, in Crohn's disease is
unknown. Methods In an integrated study with separate induction and maintenance trials, we …

Background & Aims: Tumor necrosis factor blockade has been shown to be an effective
treatment strategy in Crohn’s disease (CD). Adalimumab is a human immunoglobulin G1 (IgG 1 ) …

Background: Adalimumab induced clinical remission after four weeks in patients with active
Crohn’s disease in the CLASSIC I trial. Objective: To evaluate long term efficacy and safety …

Background Although corticosteroids are highly effective in improving symptoms of Crohn's
disease, they may have substantial toxicity. In some patients, attempts to discontinue …

Background & Aims: Intestinal luminal microflora, or their products, are likely an important
initiating factor in the pathogenesis of inflammatory bowel disease. The aim of this study was to …

Objective The aim of this study was to assess the efficacy and safety of adalimumab (ADA),
a recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for the …